|
IMUX | Immunic, Inc. |
|
|
IMUX | Immunic, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.20 |
| Leverage | 54.91% |
| Market Cap | $ 89.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -100.0m |
| Margin | 9522.56% |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.